8x8 Inc vs Hims and Hers Health Inc — how do they compare? 8x8 Inc trades at $2.11 (market cap $311.98M), while Hims and Hers Health Inc trades at $30.92 (market cap $6.55B). The key difference: Hims and Hers Health Inc is far larger — about 21× 8x8 Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and Hims and Hers Health Inc for 21 Days on average.
| EGHT | HIMS | |
|---|---|---|
Market Cap | $311.98M | $6.55B |
Volume | 1,639,086 | 14,842,814 |
Sector | Technology | Health |
52-Week High | $2.76 | $62.76 |
52-Week Low | $1.59 | $14.52 |
Typical Hold Time | 16 Days | 21 Days |
Enterprise Value | $578.90M | $7.25B |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.13, down 0.47% on the day, with a bullish technical signal supported by moving averages. The company shows strong revenue growth with $715M in 2025 and positive earnings beats in recent quarters, though profitability remains challenged with a net loss of $27M. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus is mixed with a $19.77 price target representing significant upside potential.
EGHT presents a high-risk, high-reward opportunity with substantial analyst upside but faces execution risks amid competitive pressures. The stock's current valuation at 72x P/E reflects growth expectations, but investors must weigh the company's debt load and margin challenges against its strategic positioning in cloud communications and AI innovation.
HIMS stock trades at $28.06, down 5.01% on the day, amid a bearish technical signal and negative earnings surprises. The company reported a net loss of $142 million in 2026, with a negative net income margin of -5.51%, despite revenue growth to $2.6 billion. Multiple securities class action lawsuits filed in October 2026 create significant legal overhang, while analyst consensus remains mixed with a $32.17 price target but only 35% buy ratings.
The outlook is clouded by profitability challenges and legal risks, though revenue growth offers a potential catalyst if margins improve. Investors face substantial downside risk from ongoing litigation and weak earnings, offset by analyst price targets suggesting modest upside from current levels if operational execution improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →